Key Points
- Director Brian Posner bought 2,000 shares of Dyne Therapeutics at $16.94 each, a $33,880 purchase that increased his holdings by 8.89% to 24,500 shares.
- DYN stock rose 6.6% and opened at $17.92, while the company’s market cap was about $2.96 billion and shares have traded between $8.06 and $25.00 over the past year.
- Dyne reported a smaller-than-expected quarterly loss of $0.73 per share, beating estimates, and Wall Street currently has a Moderate Buy consensus with a $35 average price target.
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) Director Brian Posner purchased 2,000 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, June 8th. The shares were bought at an average cost of $16.94 per share, for a total transaction of $33,880.00. Following the transaction, the director directly owned 24,500 shares of the company's stock, valued at $415,030. This represents a 8.89% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Dyne Therapeutics Trading Up 6.6%
Shares of DYN stock opened at $17.92 on Wednesday. The stock's fifty day moving average price is $18.26 and its two-hundred day moving average price is $18.22. The company has a market cap of $2.96 billion, a PE ratio of -5.57 and a beta of 1.09. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating analysts' consensus estimates of ($0.77) by $0.04. During the same period last year, the company posted ($1.05) earnings per share. Equities analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
DYN has been the topic of a number of research analyst reports. Wall Street Zen raised Dyne Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th. Evercore set a $33.00 target price on Dyne Therapeutics in a report on Friday, May 15th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Dyne Therapeutics in a report on Monday, March 9th. Chardan Capital reaffirmed a "buy" rating and issued a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, HC Wainwright reduced their target price on Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, March 3rd. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $35.00.
View Our Latest Stock Analysis on DYN
Institutional Investors Weigh In On Dyne Therapeutics
Several hedge funds have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock valued at $343,085,000 after acquiring an additional 14,727,667 shares in the last quarter. Vanguard Group Inc. raised its position in Dyne Therapeutics by 14.9% during the 4th quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company's stock worth $219,376,000 after purchasing an additional 1,455,151 shares during the last quarter. State Street Corp raised its position in Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company's stock worth $130,910,000 after purchasing an additional 1,423,828 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in Dyne Therapeutics by 45.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company's stock worth $101,164,000 after purchasing an additional 1,618,000 shares during the last quarter. Finally, Orbis Allan Gray Ltd bought a new position in Dyne Therapeutics during the 4th quarter worth $93,926,000. Institutional investors and hedge funds own 96.68% of the company's stock.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
